Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (September 2018)
23 slides from Microbot Medical's investor presentation, Sep 4, 2018
Slide 1: Microbot Medical: Robotizing Endoluminal Surgery
microbot medical ROBOTIZING ENDOLUMEN SURGERY BNSS BOG MEOI
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS microbot THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. (‘MICROBOT”) AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accep
Slide 3: The Initial Spark...
microbot THE INITIAL SPARK... medical
Slide 4: Evolution of Surgery...
EVOLUTION OF SURGERY... microbot ..and the revolution of robotics in healthcare Biomedical micro-robotics ‘applications Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery
Slide 5: Micro-Robotics Applications
microbot MICRO-ROBOTICS APPLICATIONS medical Mm wo Drug Delivery Marking Sensing Biomedical Occlusion micro-robotics applications Brachytherapy Hyperthermia Stem Cells. Ce Hestemie nc Ul Ablation Scaffolding ‘Annual review of BioMed, Micro-robots for MIS, 2010
Slide 6: The Medical Robotics Market
microbot THE MEDICAL ROBOTICS MARKET medical MIS Expected to Reach >$50B Market by 2019 Becoming Smaller, Automated, and More Precise
Slide 7: The Medical Robotics Market
micropot THE MEDICAL ROBOTICS MARKET icrobot & Mazor Robotics and Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a Medtronic $410 million Third Tranche Investment in Mazor Business Wire, August 30, 2017 folvenaohuen Johnson & Johnson Announces Formation of G Verb Surgical Inc
Slide 8: Our Mission
microbot medical OUR MISSION Enable all stakeholders to transform medical treatments and improve patient efficacy through our micro-invasive robotic platforms
Slide 9: Technology Platforms
TECHNOLOGY PLATFORMS microbot ViRob @ Autonomous Advancing Micro-Robot (AAMR) @ ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens TipCAT a © TipCAT is a disposable, —_—S=—s flexible, self-propelled, see & treat endoscope/catheter CardioSert @ Combin
Slide 10: ViRob First Product
VIROB FIRST PRODUCT ViRob ® Self Cleaning Shunt (SCS) @® Anovel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients
Slide 11: Slide 11
Slide 12: VP Shunt Market Opportunity
VP SHUNT MARKET OPPORTUNITY @ Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. @ Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone!? @ Over 1,000,0
Slide 13: Approximately 50% of shunts in the pediatric population fail within two years
» Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical ENS operations are often required’ ® Ventricular catheter blockage is by far the most frequent event? 1. Hydrocephalus Association. http:/iwmw hydroassoc.ora/complications-of-shunt
Slide 14: Self Cleaning Shunt (SCS) - Lab Study
SELF CLEANING SHUNT (SCS) — LAB STUDY ViRob showed the ability to prevent blockage on a shunt opening AVERAGE BLOCKAGE 100 90 80 70 60 ~70% Occlusion Free 50 20 : 10 ie) 7 1 Sscs2 SCcS3 scs4 Ctrl 4 Blockage percentage [%] mSCS2 mscS4 MSCS3 & Control 1
Slide 15: Self Cleaning Shunt (SCS) - Lab Study
ViRob SELF CLEANING SHUNT (SCS) — LAB STUDY & eee 2014 we Bristol? ns Laboratory Testing of Micro-Robotic Self-Cleaning Shunt UK Shunt Testing Lab, Cambridge University, UK CONCLUSIONS: “Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular catheter and
Slide 16: Self Cleaning Shunt (SCS) - Pre Clinical
ViRob SELF CLEANING SHUNT (SCS) — PRE CLINICAL @ Wayne State University — Goal: Test and finalize the design of the Company’s SCS, using Dr. Carolyn Harris’ bio- reactor system that mimics human brain tissue three-dimensionally — Result: Supports the SCS’s potential as a viable technology for preven
Slide 17: Organization & Infrastructure to Execute Plan
microbot medical ORGANIZATION & INFRASTRUCTURE TO EXECUTE PLAN 7
Slide 18: Robust IP Platform
ROBUST IP PLATFORM FAMILY TITLE |S PATENT/APP NO. OTHER COUNTRIES ee Granted: EP (DE, FR, GB, IT), CA, Tip Propelled Device for Motion Through a Passage US 9,997,326, SNe US 15/936,878 inflatable Chamber Device for Motion Through a US 9,427,143 noe Saas Granted: EP (DE, FR, GB, IT) US 6,430,810 Infl
Slide 19: Proven Leadership Team
PROVEN LEADERSHIP TEAM Prof. Moshe Shoham Member of the Scientific Advisory Board & Co-Founder Prof. Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 20 years, with a special focus on kinematics and dynamics of robots, sen
Slide 20: Proven Leadership Team
PROVEN LEADERSHIP TEAM David Ben Naim CFO Mr. Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial ® Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:INSL). ® Prior to t
Slide 21: Strengthened Balance Sheet
STRENGTHENED BALANCE SHEET microbot Two separate capital market transactions totaling over $13.5 million
Slide 22: Platforms, Sub-Platforms, Applications
PLATFORMS SUB-PLATFORMS APPLICATIONS MULTIPLE OPPORTUNITIES CardioSert Drug Delivery Diagnosis uro TipCAT Self Propelled Guider al ENT Uro Cardio Dialysis GYN Uro Cardio Neuro
Slide 23: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing three micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership
Microbot Medical — Investor Presentation (September 2018) on 6ix